Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. ZA1992/03213 - POLYPEPTIDES WITH AFFINITY TO LIPOPOLYSACCHARIDES AND THEIR USES

Office Afrique du Sud
Numéro de la demande 1992/03213
Date de la demande 04.05.1992
Numéro de publication 1992/03213
Date de publication 29.12.1993
Type de publication B
CIB
C08B
CCHIMIE; MÉTALLURGIE
08COMPOSÉS MACROMOLÉCULAIRES ORGANIQUES; LEUR PRÉPARATION OU LEUR MISE EN UVRE CHIMIQUE; COMPOSITIONS À BASE DE COMPOSÉS MACROMOLÉCULAIRES
BPOLYSACCHARIDES; LEURS DÉRIVÉS
C07C
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
CCOMPOSÉS ACYCLIQUES OU CARBOCYCLIQUES
C08L
CCHIMIE; MÉTALLURGIE
08COMPOSÉS MACROMOLÉCULAIRES ORGANIQUES; LEUR PRÉPARATION OU LEUR MISE EN UVRE CHIMIQUE; COMPOSITIONS À BASE DE COMPOSÉS MACROMOLÉCULAIRES
LCOMPOSITIONS CONTENANT DES COMPOSÉS MACROMOLÉCULAIRES
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
C07K 14/43509
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
43504from invertebrates
43509from crustaceans
Déposants SEIKAGAKU KOGYO KABUSHIKI KAISHA
Inventeurs NOBUTAKA FUJII
NOAKI YAMAMOTO
AKIYOSHI MATSUMOTO
MICHINORI WAKI
Mandataires SPOOR & FISHER
Données relatives à la priorité 3-130410 02.05.1991 JP
Titre
(EN) POLYPEPTIDES WITH AFFINITY TO LIPOPOLYSACCHARIDES AND THEIR USES
Abrégé
(EN)
A novel polypeptide sequence having the formula

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
A,-A2-Cys-A2-A3-A3-Cys-A2-A3-Gly-A2-Cys-A2-A3-A3-Cys-A4-A5

in which

A, is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine,
A2 is a tyrosine, phenylalanine or tryptophan
residue,
A3 is an arginine or lysine residue,
A4 is at least one and no more than two amino
acids selected from the group consisting of lysine and arginine, and
A5 is an -OH or an NH2, is described. The polypeptide may be used in a pharmaceutical composition as an antimicrobial or antiviral agent,
specifically as an anti-HIV agent.